Factors associated with the grades of benign prostatic hyperplasia

Authors

Keywords:

comorbidity; healthy lifestyle; prostatic diseases; prostatic hyperplasia; risk factors

Abstract

Introduction: benign prostatic hyperplasia is one of the most common urological conditions in older adult men and represents a significant cause of lower urinary tract symptoms.

Objective: to determine the association between clinical, nutritional, familial, and lifestyle-related factors and the grades of benign prostatic hyperplasia.

Methods: an observational, analytical, cross-sectional study was carried out. The sample consisted of 25 patients diagnosed with benign prostatic hyperplasia, selected through simple random sampling. Data were obtained from clinical records using a data collection form. Clinical and nutritional variables, family history, and lifestyle-related factors were analyzed. Statistical analysis included descriptive procedures, bivariate analysis, and a generalized linear multivariate model with a Poisson distribution and a logarithmic link function.

Results: the 71–75 age group was the most prevalent (44.00 %). The most common grades were grade II (32.00 %) and grade IV (28.00 %). Family history of arterial hypertension, dietary habits, and nutritional status showed Exp(B) values ​​greater than one, while physical activity and coffee consumption showed values ​​less than one.

Conclusions: clinical, nutritional, and lifestyle-related variables showed associations with the grades of benign prostatic hyperplasia, highlighting the importance of strengthening prevention and early diagnosis strategies.

Downloads

Download data is not yet available.

Author Biographies

Yolanda Victoria Yescas Lopéz, Universidad Central de Nicaragua. Managua, Nicaragua.

Doctora en Medicina y Cirugía. Maestrante en Gestión de la Educación de la Universidad Cardenal Miguel Obando Bravo. Docente de la Facultad de Ciencias Médicas. 

Débora Rebeca Hernández Flores, Universidad Central de Nicaragua. Facultad de Ciencias Médicas. Managua, Nicaragua.

Máster en Gestión y docencia universitaria. Licenciada en Química y Farmacia. Docente de Investigación.

María Fernanda Valverde Calero, Universidad Central de Nicaragua. Facultad de Ciencias Médicas. Sede Jinotepe, Carazo. Managua, Nicaragua.

Médico General. 

Soliett Isamara Ramos Mendoza, Universidad Central de Nicaragua. Facultad de Ciencias Médicas. Sede Jinotepe, Carazo. Managua, Nicaragua.

Médico General. 

References

1. Infante-Hernández S, Gómez-Rivas J, Moreno-Sierra J. Hiperplasia benigna de próstata. Med Clin (Barc) [Internet]. 2024 [citado 7 Ene 2026];163(8):407–14. Disponible en: https://www.sciencedirect.com/getaccess/pii/S0025775324003075/purchase

2. Devlin CM, Simms MS, Maitland NJ. Benign prostatic hyperplasia: what do we know? BJU Int. [Internet]. 2021 [citado 7 Ene 2026];127(4):389–99. Disponible en: https://bjui-journals.onlinelibrary.wiley.com/doi/epdf/10.1111/bju.15229

3. Gacci M, Corona G, Vignozzi L, Salvi M, Serni S, De Nunzio C, et al. Metabolic syndrome and benign prostatic enlargement: a systematic review and meta-analysis. BJU Int. [Internet]. 2015 [citado 11 Ene 2026];115(1):24–31. Disponible en: https://bjui-journals.onlinelibrary.wiley.com/doi/epdf/10.1111/bju.12728

4. Zi H, Liu MY, Luo LS, Huang Q, Luo PC, Luan HH, et al. Global burden of benign prostatic hyperplasia, urinary tract infections, urolithiasis, bladder cancer, kidney cancer, and prostate cancer from 1990 to 2021. Mil Med Res. [Internet]. 2024 [citado 11 Ene 2026];11(1):64. Disponible en: https://link.springer.com/content/pdf/10.1186/s40779-024-00569-w.pdf

5. Launer BM, McVary KT, Ricke WA, Lloyd GL. The rising worldwide impact of benign prostatic hyperplasia: the global burden of benign prostatic hyperplasia exceeds all other genitourinary diseases. BJU Int. [Internet]. 2021 [citado 12 Ene 2026];127(6):722–8. Disponible en: https://bjui-journals.onlinelibrary.wiley.com/doi/epdf/10.1111/bju.15286

6. Chughtai B, Lee R, Te A, Kaplan S. Role of inflammation in benign prostatic hyperplasia. Rev Urol. [Internet]. 2011 [citado 12 Ene 2026];13(3):147–50. Disponible en: https://bjui-journals.onlinelibrary.wiley.com/doi/epdf/10.1111/bju.15286

7. Phua TJ. The etiology and pathophysiology genesis of benign prostatic hyperplasia and prostate cancer: a new perspective. Medicines (Basel) [Internet]. 2021 [citado 15 Ene 2026];8(6):30. Disponible en: https://www.mdpi.com/2305-6320/8/6/30/pdf?version=1623402743

8. Lepor H. Pathophysiology of benign prostatic hyperplasia: insights from medical therapy for the disease. Rev Urol. [Internet]. 2009 [citado 15 Ene 2026];11(Suppl 1):S9–13. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/pmid/20126609/

9. Bang WJ, Choi HG, Kang HS, Kwon MJ, Kim JH, Kim J H, et al. Increased risk of benign prostate hyperplasia (BPH) in patients with gout: A longitudinal follow-up study using a national health screening cohort. Diagnostics (Basel) [Internet]. 2023 [citado 15 Ene 2026];14(1):55. Disponible en: https://www.mdpi.com/2075-4418/14/1/55/pdf?version=1703642091

10. Sandhu JS, Bixler BR, Dahm P, Goueli R, Kirkby E, Stoffel JT, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH): AUA guideline amendment 2023. J Urol. [Internet]. 2024 [citado 15 Ene 2026];211(1):11–9. Disponible en: https://www.auajournals.org/doi/epdf/10.1097/JU.0000000000003698

11. Widerstrom Isea H, Cañete García S, Venegas Varas F, Gardeweg Páez V, Lavín Ferrada P, Madriaza Valenzuela V. Hiperplasia prostática benigna: estudio cuantitativo sobre la epidemiología chilena. Rev Conflu. [Internet]. 2024 [citado 15 Ene 2026];7. Disponible en: https://revistas.udd.cl/index.php/confluencia/es/article/view/1115/838

12. Silva-Juárez YE, Torres-Matamoros HL. Perfil clínico y calidad de vida en pacientes con hiperplasia prostática benigna de un hospital de León, Nicaragua [Internet]. León: Universidad Nacional Autónoma de Nicaragua; 2024. [citado 15 Ene 2026]. Disponible en: http://riul.unanleon.edu.ni:8080/jspui/bitstream/123456789/10171/1/254752.pdf

13. Bodan-Matus MI, Galán-Carranza AL, Herrera-Flores JE. Comportamiento clínico de la hiperplasia prostática benigna en pacientes atendidos por el servició de Urología del Hospital José Nieborowski, Boaco de junio 2022 – enero 2023. Universidad Católica Redemptoris Mater; 2023. [citado 15 Ene 2026]. Disponible en: http://repositorio.unica.edu.ni/120/1/Informe%20final%20terminado%20de%20Proyecto%20Monografico%20HPB%2C%20Boaco.pdf

14. Asociación Médica Mundial. Declaración de Helsinki de la AMM. Principios éticos para las investigaciones médicas en seres humanos. Ratificada en la 75th WMA General Assembly, Helsinki, Finland, october 2024 [Internet]. Helsinki: 18ª Asamblea Mundial; 1964 [citado 15 Ene 2026]. Disponible en: https://www.wma.net/policies-post/wma-declaration-of-helsinki/

15. Ng M, Leslie SW, Baradhi KM. Benign prostatic hyperplasia. Treasure Island (FL): StatPearls Publishing; 2026. Disponible en: https://www.ncbi.nlm.nih.gov/books/NBK558920/

16. Lerner LB, McVary KT, Barry MJ, Bixler BR, Dahm P, Das AK, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA GUIDELINE PART I-initial work-up and medical management. J Urol. [Internet]. 2021 [citado 15 Ene 2026];206(4):806–17. Disponible en: https://www.auajournals.org/doi/epdf/10.1097/JU.0000000000002183

17. Xiong Y, Zhang Y, Li X, Qin F, Yuan J. The prevalence and associated factors of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in aging males. Aging Male. [Internet]. 2020 [citado 15 Ene 2026];23(5):1432–9. Disponible en: https://www.tandfonline.com/doi/epdf/10.1080/13685538.2020.1781806?needAccess=true

18. Arias-Salazar CM, O. León- Giraldo H, D. Iregui-Parra J, J. Moreno-Rodríguez L, M. Henao-Cardona L, Castaño-Orozco M, et al. Correlación del volumen prostático mediante ecografía y peso del estudio anatomopatológico posterior a prostatectomía en clínica de tercer nivel en Cali. Rev Urol Colomb [Internet]. 2025 [citado 15 Ene 2026];33(2). Disponible en: https://urologiacolombiana.com/wp-content/uploads/2025/07/ruc_25_34_2_072-080.pdf

19. Kim EH, Larson JA, Andriole GL. Management of benign prostatic hyperplasia. Annu Rev Med. [Internet]. 2016 [citado 26 Ene 2026];67(1):137–51. Disponible en: https://www.annualreviews.org/content/journals/10.1146/annurev-med-063014-123902

Downloads

Published

2026-10-25

How to Cite

1.
Yescas Lopéz YV, Hernández Flores DR, Valverde Calero MF, Ramos Mendoza SI. Factors associated with the grades of benign prostatic hyperplasia . Mediciego [Internet]. 2026 Oct. 25 [cited 2026 Nov. 13];32:e4324. Available from: https://revmediciego.sld.cu/index.php/mediciego/article/view/4324

Issue

Vol. 32 (2026)

Section

Original article

License

Copyright (c) 2026 Yolanda Victoria Yescas Lopéz, Débora Rebeca Hernández Flores; María Fernanda Valverde Calero; Soliett Isamara Ramos Mendoza

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Those authors who have publications with this journal accept the following terms of the License CC Attribution-NonCommercial 4.0 International (CC BY-NC 4.0):

You are free to:

  • Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
  • Adapt — remix, transform, and build upon the material for any purpose, even commercially.

The licensor cannot revoke these freedoms as long as you follow the license terms.

Under the following terms:

  • Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

The journal is not responsible for the opinions and concepts expressed in the works, which are the exclusive responsibility of the authors. The Editor, with the assistance of the Editorial Committee, reserves the right to suggest or request advisable or necessary modifications. Original scientific works are accepted for publication, as are the results of research of interest that have not been published or sent to another journal for the same purpose.

The mention of trademarks of specific equipment, instruments or materials is for identification purposes, and there is no promotional commitment in relation to them, neither by the authors nor by the editor.